Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H ( (HK:1541) ) just unveiled an update.
ImmuneOnco Biopharmaceuticals has received approval from the National Medical Products Administration of China to initiate a clinical trial for IMC-003/IMM72, a treatment for pulmonary arterial hypertension. This development marks a significant step in the company’s efforts to advance its pipeline of innovative therapies, potentially enhancing its position in the biopharmaceutical industry.
More about ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biopharmaceutical company based in China, focusing on the development and commercialization of innovative therapeutic products. The company specializes in genetic engineering and holds global intellectual property rights for its products, including the ActRIIA-Fc fusion protein IMC-003/IMM72.
Average Trading Volume: 5,020,704
Technical Sentiment Signal: Buy
Current Market Cap: HK$9.81B
For detailed information about 1541 stock, go to TipRanks’ Stock Analysis page.